Since we’re talking about HCV relapse, I’d like to give credit to VRTX for the design of the phase-2 Telaprevir + VX-222 trial that’s the subject of the board survey in #msg-50836757. A new twist in this trial is the *2-week* rule in the algorithm that specifies whether a given patient in one of the non-SoC arms will get treatment for 12 weeks (all-oral) or 36 weeks (12 weeks all-oral + 24 weeks SoC).
Requiring patients to have undetectable VL after only 2 weeks rather than the usual 4 weeks is plainly an attempt to minimize relapses following all-oral treatment. Whether this wrinkle will be consequential remains to be seen, but I think it’s a good piece of trial-design work by VRTX.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.